**PreludeDx Presents New Data Highlighting Ability of DCISionRT® to Predict Benefit of Radiation Therapy in DCIS Patients, Independent of Endocrine Therapy (ET)**

LAGUNA HILLS, Calif., May 30, 2024 /PRNewswire/-- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced that it will share data demonstrating the power of its DCISionRT® test to better predict radiation therapy (RT) benefit in comparison to clinicopathologic risk factors for women with ductal carcinoma in situ (DCIS) at The American Society of Clinical Oncology (ASCO), to be held on May 31 – June 4, 2024 at the McCormick Place in Chicago.

Of particular importance, the DCISionRT biosignature identified a low-risk group of patients with no significant benefit from ET or RT after breast-conserving surgery.

"We look forward to sharing the latest data at ASCO that reaffirms DCISionRT's prognostic and predictive value of the test to reclassify recurrence risk based on clinicopathology alone, and that the test's impact is not altered by use of endocrine therapy," said Dan Forche, President and CEO of PreludeDx.

**PreludeDx American Society of Clinical Oncology (ASCO) Poster to Be Presented**

**Title:** *Identification of DCIS patients with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature*
**Presenter:** Pat W. Whitworth, MD, Nashville Breast Center, Nashville, TN
**Date:** Sunday, June 2, 9:00 a.m. CT

**About DCISionRT for Breast DCIS**

DCISionRT is the *only* risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from the University of California San Francisco, and built on research that began with funding from the National Cancer Institute, enables physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman's individual tumor biology along with other pathologic risk factors and provide a personalized recurrence risk. The test provides a Decision Score™ that identifies a woman's risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

**About PreludeDx**

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk™. PreludeDx is a Fjord Ventures portfolio company.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.



**Media Contact**
Chris Emery
cemery@preludedx.com

**Investor Contact**
Andrew Wade
awade@preludedx.com